Capsule endoscopy (CE) has been established as a convenient method for evaluating the small bowel. CE provides a higher diagnostic yield than barium contrast radiography of the small bowel or enteroscopy [1 -4]. It is safe, painless, and well-tolerated [5] . Despite these advantages, the diagnostic yield of CE may be restricted by some limitations, including technical difficulties, inability of some patients to swallow the capsule, the relatively poor quality of the small-bowel images, and the frequent inability of this modality to allow complete assessment of the small bowel; in 20 -30 % of the cases, the capsule does not reach the cecum within the imaging period [6 -8]. In addition, overall results differ among studies, with the reported percentage of cases of incomplete visualization of the mucosal surfaces due to bubbles, or luminal residue obscuring the view, especially in the distal small bowel, varying from 5 % to 30 % [9 -12] .
Background and study aims Lubiprostone has been reported to be an anti-constipation drug. The aim of the study was to investigate the usefulness of lubiprostone both for bowel preparation and as a propulsive agent in small bowel endoscopy.
Patients and methods
This was a double-blind, placebocontrolled, 2-way crossover study of subjects who volunteered to undergo capsule endoscopy (CE). A total of 20 subjects (16 male and 4 female volunteers) were randomly assigned to receive a 24-μg tablet of lubiprostone 120 minutes prior to capsule ingestion for CE (L regimen), or a placebo tablet 120 minutes prior to capsule ingestion for CE (P regimen). Main outcome was gastric transit time (GTT) and small-bowel transit time (SBTT). Secondary outcome was adequacy of small-bowel cleansing and the fluid score in the small bowel. The quality of the capsule endoscopic images and fluid in the small bowel were assessed on 5-point scale.
Results The capsule passed into the small bowel in all cases. Median GTT was 57.3 (3 -221) minutes for the P regimen and 61.3 (10 -218) minutes for the L regimen (P = 0.836). Median SBTT was 245.0 (164 -353) minutes for the P regimen and 228.05 (116 -502) minutes for the L regimen (P = 0.501). The image quality score in the small bowel was 3.05 ± 1.08 for the P regimen and 3.80 ± 0.49 for the L regimen (P < 0.001). The fluid score in the small bowel was 2.04 ± 1.58 for the P regimen and 2.72 ± 1.43 for the L regimen (P < 0.001). There was a significant difference between the 2 regimens with regard to image quality. The fluid score was more plentiful for the L regimen than for the P regimen. There were no cases of capsule retention or serious adverse events in this study.
Conclusion
Our study showed that use of lubiprostone prior to CE significantly improved visualization of the small bowel during CE as a result of inducing fluid secretion into the small bowel.
Several studies have examined the possibility of shortening transit time and improving bowel cleanness by using different medications for bowel preparation and prescribing different fasting periods [13, 14] . Current bowel preparation protocols, although still not standardized, usually include clear liquids the day before, and restraint from drinking and eating within 8 to 10 hours before capsule ingestion. Comparisons of this type of preparation with gut lavage or oral sodium phosphate regimens have shown similar efficacy for all the regimens [15] . Therefore, the optimal preparation method for small-bowel CE has not yet been established.
Lubiprostone (Amitiza; ABBOTT JAPAN CO., LTD, Tokyo) selectively activates the type-2 chloride channels in the apical membrane of the gastrointestinal epithelium, inducing net fluid secretion. It is currently approved by the US Food and Drug Administration for treatment of chronic idiopathic constipation, constipation-predominant irritable bowel syndrome in women and opioid-induced constipation in patients with chronic non-cancer pain. The proposed primary mechanism of action of lubiprostone in the gastrointestinal tract is increased chloride ion transport into the intestinal lumen by the drug caused by the opening of ClC-2, which results in increased intestinal secretion and accelerated mass transit [16, 17] . Transit time studies by Camilleri et al. [18] revealed that lubiprostone accelerated small bowel transit and colonic transit times. Prior to this report, some clinical studies by our group showed that lubiprostone decreased gastric and small-bowel transit time [19 -20] . Meta-analysis showed differing results for gastric and small-bowel transit times and the reasons for that are not yet clear [21 -22] .
To solve this problem, we first examined the preliminary study to find the optimum intake time for lubiprostone before the CE [19] , then we designed a double-blind, placebo-controlled 2-way crossover trial to investigate the usefulness of lubiprostone, both as a bowel preparation agent and as a propulsive agent for small bowel endoscopy.
Patients and methods

Trial design
This was a double-blind, placebo-controlled, 2-way crossover study of subjects who volunteered to undergo CE. In all subjects, CE was performed with the PillCam SB2 CE system (Given Imaging Ltd), and the images were viewed with the Rapid 5 Reader. The subjects were randomly assigned to receive a 24-μg tablet of lubiprostone 120 minutes prior to capsule ingestion for CE (L regimen), or a placebo tablet 120 minutes prior to capsule ingestion for CE (P regimen). Subjects receiving either regimen were allowed to drink mineral water (maximum 1000 mL) 2 hours after swallowing the capsule and to eat a light meal (balanced food: calorie mate ® 800 kcal) after 4 hours. The subjects did not eat and drink anything else until the test was completed. After 8 hours, they returned to the endoscopy unit where the recorder was removed and the images were downloaded. Each of the test conditions were separated by a washout period of at least 7 days.
Participants
The study was performed between April 2014 and June 2014 at Yokohama City University School of Medicine. The subjects were 16 male volunteers and 4 female volunteers (average age: 32.9 years; age range: 29 -53 years). Baseline evaluations included a medical history, physical examination, and collection of demographic data (▶ Table 1 ). Exclusion criteria were a history of gastric or intestinal surgery, clinical or suspected abnormalities of gastric emptying, pregnancy or possible pregnancy, age < 18 years, and a history of intake of medications during the previous week that could potentially affect the gastrointestinal motility.
▶ 
Intervention
Subjects receiving either regimen were instructed to have nothing by mouth for at least 8 hours prior to capsule ingestion for CE. Lubiprostone or placebo was administered 120 minutes prior to capsule ingestion in accordance with the protocols described above. The PillCam Small Bowel CE system (Given Imaging, Yoqneam, Israel) with the PillCam SB2 capsule and Rapid 5 software platform were used for the study. All CE images were read by 2 investigators (M. I. and M. M.), both of whom were blinded to the group allocation status of the subjects. Small bowel examination was considered to be complete if the capsule had passed into the colon.
Outcome
The main outcome was gastric transit time (GTT) and smallbowel transit time (SBTT). The secondary outcome was adequacy of small-bowel cleansing and the fluid score in the small-bowel.
Gastric and small-bowel transit times
GTT was calculated from the time the capsule entered the stomach until it crossed the pylorus. SBTT was determined as the time from the first duodenal image until the capsule entered the colon, and could be calculated only in cases in which the capsule had reached the colon.
Adequacy of bowel preparation
Quality assessment of the capsule endoscopic images was made in accordance with the scale used by Aymer et al., with some modification [17, 23 -25] . We used a 5-point scale (0 -4) based on the percentage of the capsule images that were unimpaired by presence of debris or dark luminal fluid (4, 100 -80 %; 3, 80 -60 %; 2, 60 -40 %; 1, 40 -20 %; 0, 20 -0 %). The average scores for 5-minute segments of the video were assessed from capsule entry into the proximal duodenum (0 % of the SBTT) and for every 10 % of the SBTT thereafter, with the score for the final segment recorded in the terminal ileum (100 % of the SBTT). 
Ethics
The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Yokohama City University Hospital. All the patients provided their written informed consent.
Statistical analysis
Statistical evaluation was performed using the t test and Wilcoxon's signed rank test. The level of significance was set at P < 0.05. All statistical analyses were performed with EZR (Saitama Medical Center, Jichi Medical University), which is a graphical user interface for R (The R Foundation for Statistical Computing). In other words, it is a modified version of the R commander designed to add statistical functions frequently used in biostatistics [26, 27] .
Results
All 20 enrolled subjects completed the study. The subjects were divided into 2 groups (P regimen, L regimen) and their characteristics are shown in ▶ Table 1 . No significant difference was seen between the 2 s groups. No adverse events (AEs) occurred during the study. All subjects received placebo and lubiprostone in a cross-over setup and swallowed the SB2 capsule, with the endoscopic images recorded for 8 hours. There were no cases of capsule retention after the study was completed. The capsule passed into the small bowel in all cases. Median GTT observed was 57.3 (3 -221) minutes for the P regimen and 61.3 (10 -218) minutes for the L regimen (P = 0.836). Median SBTT observed was 245.0 (164 -353) minutes for the P regimen and 228.05 (116 -502) minutes for the L regimen (P = 0.501). The data are summarized in ▶ Table 2 .
The image quality scores were 3.58 ± 0.67, 3.35 ± 0.8, 2.1 ± 1.15 and 3.05 ± 1.08 for the P regimen, 3.95 ± 0.29, 3.85 ± 0.39 3.58 ± 0.67 and 3.80 ± 0.49 for the L regimen in proximal (P < 0.001), middle (P < 0.001), distal (P < 0.001) and all (P < 0.001) of the small bowel. Fluid scores were 2.73 ± 1.35, 2.06 ± 1.60, 1.30 ± 1.45 and 2.04 ± 1.58 for the P regimen, 3.57 ± 0.87, 2.71 ± 1.40, 1.87 ± 1.44 and 2.72 ± 1.43 for the L regimen in ▶ the proximal (P < 0.001), middle (P < 0.001), distal (P < 0.001) and all (P < 0.001) of the small bowel. The data are summarized in ▶ Table 3 . Image quality became worse as the capsule progressed more distally. The views were impaired by bile, residue, and bubble artifacts. On the other hand, image quality scores for the L regimen tended to be better than those for the P regimen for all small bowel segments. There was a significant difference between the 2 regimens with regard to image quality (P < 0.001) (▶ Fig. 1 ). On the other hand, the amount of fluid was more plentiful with the L regimen than with the P regimen for all small bowel segments (▶ Fig. 2 ). There were no cases of capsule retention or serious AEs in this study.
Discussion
This study was designed to evaluate the effect of lubiprostone on the capsule transit time through the gastrointestinal lumen and its effectiveness as a bowel preparation agent for improving the quality of capsule imaging of the small bowel. Lubiprostone improved the imaging quality of the small bowel as compared to placebo. Lubiprostone did not improve the SBTT and did not delay the GTT.
Lubiprostone is approved to treat chronic constipation, constipation-predominant irritable bowel syndrome and opioid-induced constipation in non-cancer-related chronic pain. The proposed primary mechanism of action is an increase in chloride ion transport into the intestinal lumen caused by opening up by the drug of ClC-2 channels, leading to increased intestinal secretion and accelerated mass transit. GTT following administration of lubiprostone was similar to that after administration of placebo. Our findings differ from those in the study reported by Camilleri et al. [18] , who reported finding evidence of delayed gastric emptying following administration of lubiprostone. The main side effect of lubiprostone was nausea, possibly related to delayed gastric emptying [18 -22] . In Phase II trials, nausea was reported in as many as 33 % of patients receiving 48 μg of lubiprostone daily [28] . Nausea was the most common side effect of lubiprostone, reported in up to 31 % of patients in 1 study [29] . Several possible explanations for nausea have been suggested, including delayed gastric emptying, small intestinal distention secondary to increased gastric secretion, change in gastrointestinal sensation, and/or additional actions of lubiprostone on gastrointestinal motility [18 -22] . However, the precise mechanism of nausea associated with lubiprostone remains unclear.
SBTT following administration of lubiprostone was similar to that after administration of placebo. Our findings differ from those of the study by Camilleri et al. [18] in 2006. They found a significant acceleration of SBTT along with accelerated colonic transit time. However, Hooks et al. [20] showed that lubiprostone did not decrease SBTT. Our preliminary study [19] also suggested that lubiprostone has been shown to accelerate overall colonic transit without significantly changing the rate of emptying of the ascending colon [17] . With the proximal colon likely reabsorbing the increased fluid load from the small intestine, it is postulated that a primary motor effect on the colon beyond the ascending portion may be responsible for this effect [30] . Similarly, presence of a possible direct smooth muscle effect of lubiprostone on the rest of the gastrointestinal tract has also been suggested.
Lubiprostone selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in net fluid secretion [20] . It has been approved by the FDA for treatment of chronic idiopathic constipation and constipation-predominant IBS. Recent studies revealed that it accelerates small-bowel transit as well as colonic transit time [21] .
The use of polyethylene glycol (PEG) before capsule administration has yielded mixed results on intestinal propulsion and bowel preparation efficacy. There are 2 reports of studies in which PEG was given after capsule administration for CE, both of which showed promising results. Fireman et al. [31] reported retrospectively that patients who received 1.5 L of PEG 12 hours before capsule ingestion and 1.5 L of PEG 1 hour after capsule ingestion showed significant shortening of transit time through the stomach and small bowel as compared to patients who were bowel-prepared with sodium phosphate and those with no colon preparation. Endo et al. [20] used a standard liquid diet and nothing by mouth for initial preparation and gave patients 500 mL of PEG 30 minutes after capsule ingestion. Administration of PEG post-capsule ingestion resulted in an increased rate of cecal entry of the capsule and improved distal small bowel imaging.
It has been reported that use of prokinetics such as metoclopramide [23, 25] , erythromycin [14] and mosapride [32] may decrease randomness in the rate of gastric emptying and reduce SBTT. Selby [23] reported that administration of oral metoclopramide before capsule administration reduced GTT with no effect on SBTT, but still had a positive effect by increasing the percentage of capsules reaching the cecum. Metoclopramide, with the addition of senna and citrate of magnesia for bowel preparation, has also been shown to improve both GTT and SBTT. Metoclopramide has several actions that may account for its favorable influence on capsule transit time. Its main effect is in the proximal gastrointestinal tract. It improves gastric tone and peristalsis, relaxes the pyloric sphincter, and improves antroduodenal coordination [33] by a combination of its cholinergic and antidopaminergic effects [34] .
The current study has some limitations. First, the number of study subjects was small, although statistically significant differences in image quality score and fluid score in the small bowel were observed between the 2 study groups. Second, our results may be biased, because only a few female subjects were enrolled in this study. Some studies have reported an influence of gender on gastrointestinal motility, with transit time in females tending to be longer than that in males [35 -39] .
Conclusion
Our study showed that use of lubiprostone prior to CE significantly improved visualization of the small bowel during CE as a result of induction of fluid secretion into the small bowel.
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